| Acute Ischemic Stroke Management | Lifetime | 257 | CN 7 | 99.18 |
| Cerebrovascular and Carotid Artery Diseases | Lifetime | 319 | CN 6 | 99.07 |
| Stroke Rehabilitation and Recovery | Lifetime | 433 | CN 9 | 98.30 |
| Intracerebral and Subarachnoid Hemorrhage Research | Lifetime | 218 | CN 9 | 98.30 |
| Venous Thromboembolism Diagnosis and Management | Lifetime | 795 | CN 6 | 98.03 |
| Antiplatelet Therapy and Cardiovascular Diseases | Lifetime | 909 | CN 15 | 96.33 |
| Neuroprotection in Stroke and Neurodegeneration | Lifetime | 608 | CN 19 | 94.55 |
| Neurosurgical Procedures and Complications | Lifetime | 573 | CN 15 | 95.32 |
| Neurological Disease Mechanisms and Treatments | Lifetime | 801 | CN 99 | 94.10 |
| Neurological and metabolic disorders | Lifetime | 425 | CN 5 | 92.81 |
| Cardiovascular Health and Risk Factors | Lifetime | 953 | CN 110 | 89.58 |
| Neurological Complications and Syndromes | Lifetime | 979 | CN 32 | 87.53 |
| Acute Ischemic Stroke Management | 2021-2025 | 20 | CN 3 | 99.67 |
| Cerebrovascular and Carotid Artery Diseases | 2021-2025 | 31 | CN 4 | 99.41 |
| Intracerebral and Subarachnoid Hemorrhage Research | 2021-2025 | 17 | CN 3 | 98.96 |
| Stroke Rehabilitation and Recovery | 2021-2025 | 107 | CN 20 | 97.83 |
| Venous Thromboembolism Diagnosis and Management | 2021-2025 | 229 | CN 8 | 97.37 |
| Antiplatelet Therapy and Cardiovascular Diseases | 2021-2025 | 117 | CN 9 | 97.09 |
| Neurosurgical Procedures and Complications | 2021-2025 | 72 | CN 3 | 96.27 |
| Neuroprotection in Stroke and Neurodegeneration | 2021-2025 | 49 | CN 4 | 93.28 |
| Cardiovascular Health and Disease Prevention | 2021-2025 | 171 | CN 23 | 93.88 |
| Neurological Disease Mechanisms and Treatments | 2021-2025 | 107 | CN 42 | 92.51 |
| Atrial Fibrillation Management and Outcomes | 2021-2025 | 969 | CN 42 | 93.66 |
| Traumatic Brain Injury and Neurovascular Disturbances | 2021-2025 | 750 | CN 56 | 91.30 |
| Lipoproteins and Cardiovascular Health | 2021-2025 | 610 | CN 41 | 89.65 |
| Inflammatory Biomarkers in Disease Prognosis | 2021-2025 | 341 | CN 143 | 84.69 |
| Hyperglycemia and glycemic control in critically ill and hospitalized patients | 2021-2025 | 167 | CN 7 | 86.45 |
| Intracranial Aneurysms: Treatment and Complications | 2021-2025 | 725 | CN 139 | 89.10 |
| Spinal Hematomas and Complications | 2021-2025 | 113 | CN 14 | 81.93 |
| Neurological Complications and Syndromes | 2021-2025 | 182 | CN 33 | 80.43 |
| Atherosclerosis and Cardiovascular Diseases | 2021-2025 | 846 | CN 179 | 76.59 |
| Neurological and metabolic disorders | 2021-2025 | 160 | CN 15 | 74.80 |
| Moyamoya disease diagnosis and treatment | 2021-2025 | 820 | CN 269 | 59.40 |
| Cerebrovascular and genetic disorders | 2021-2025 | 388 | CN 83 | 54.84 |
| Protease and Inhibitor Mechanisms | 2021-2025 | 897 | CN 237 | 54.80 |
| Studies on Chitinases and Chitosanases | 2021-2025 | 583 | CN 266 | 41.93 |
